
|Articles|February 1, 2003
FDA clinical trial: Myopia study shows benefits of wavefront-guided ablations
Orlando-Six-month results from an FDA clinical trial indicate that customized wavefront-guided LASIK for treatment of myopia with the WavePrint system (VISX) is associated with safe and effective outcomes exceeding FDA targets. The wavefront-guided LASIK is also effective for minimizing increases in higher-order aberrations that can accompany conventional LASIK.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Belite Bio releases topline results from phase 3 DRAGON trial of Tinlarebant for STGD1
2
Lotus submits NDA in South Korea for LENZ’s presbyopia treatment VIZZ
3
Collarettes common but largely stable in moderate-to-severe dry eye patients
4
EYDENZELT, Celltrion’s biosimilar referencing EYLEA, approved in Canada
5

















































.png)


